<DOC>
	<DOCNO>NCT00130117</DOCNO>
	<brief_summary>The purpose study determine whether administration investigational medication call leptin ( r-metHuLeptin ) replacement dos improve bone health , reproductive function , hormone level , immune function , overall sense well-being woman hypothalamic ( exercise-induced ) amenorrhea ( HA ) treat oral contraceptive pill ( OCPs ) , compare placebo . Women hypothalamic amenorrhea low leptin level . This study base hypothesis relative leptin deficiency woman hypothalamic ( exercise-induced ) amenorrhea may reason lack menstrual cycle , hormone abnormality , bone loss associate condition .</brief_summary>
	<brief_title>Study Leptin Treatment Hypothalamic Amenorrhea</brief_title>
	<detailed_description>Leptin hormone secrete fat cell normal condition act brain regulate energy usage hormone level . Women HA regular period low leptin level may also hormone abnormality well loss bone density ( osteopenia osteoporosis ) . This study evaluate leptin ( fat cell hormone normally circulate blood ) affect bone density , menstrual period , hormone level , bone metabolism ( bone form turn ) , immune function ( well body fight infection ) , metabolic rate ( many calorie use rest ) , overall sense well-being appetite woman HA ( i.e . regular menstrual period due low level pituitary hormone regulate estrogen production ovary ) . It also investigate whether leptin replacement use adjunct current standard care HA patient , i.e . OCPs . Part A Randomized , placebo-controlled 36-week study . Part B Optional open-label 52-week study . There also optional Reward Sub-study , include healthy control , design investigate leptin 's relation reward process collect participant ' brain behavioral response image ( e.g. , picture food vs. non-food ) . Brain response collect also assessed via functional Magnetic Resonance Imaging ( fMRI ) . Comparison : Part A = leptin-treated group placebo-treated group Part B optional sub study = leptin-treated group health control</detailed_description>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Inclusion criterion HA subject Hypothalamic amenorrhea least 6 month duration low normal LH FSH , e.g . due strenuous exercise ( run &gt; 20 mile per week equivalent ) low weight Can secondary HA OR primary HA pubertal development normal screen labs Age 1835 year old Body weight within +/ 15 % ideal body weight stable 6 month ( change &gt; 5 lb ) Baseline leptin &lt; 5 ng/mL ( except Cognitive SubStudy Baseline visit baseline leptin great 5ng/mL ) Inclusion criterion eumenorrheic control Reward Substudy Normal menstrual cycle ( 25 35 day ) Age 1835 Body weight within +/ 15 % ideal body weight stable 6 month ( change &gt; 5 lb ) Baseline leptin &gt; 5 ng/mL Exclusion criterion : We exclude subject : Significant medical history may affect concentration hormone study ability participate study renal hepatic disease ( creatinine &gt; 1.4 , AST/ALT &gt; 2x upper limit normal ) diagnose diabetes mellitus myocardial ischemia malignancy ( basal cell carcinoma skin situ carcinoma cervix ) malabsorption alcoholism , drug abuse , smoke active eating disorder depression psychiatric disease anemia ( Hb10 gm/dL 2 occasion ) Conditions contraindicate oral contraceptive use : Thrombophlebitis thromboembolic disorder A past history deep vein thrombophlebitis thromboembolic disorder Cerebral vascular coronary artery disease Known suspect carcinoma breast Carcinoma endometrium know suspected estrogendependent neoplasia Undiagnosed abnormal genital bleeding Hepatic adenoma carcinoma Cholestatic jaundice pregnancy jaundice prior OCP use Other endocrine cause amenorrhea , e.g . hyperprolactinemia hypothyroidism hyperthyroidism Cushing 's syndrome congenital adrenal hyperplasia ( elevated 17 OH progesterone ) polycystic ovarian syndrome ( elevate androgen LH/FSH ratio &gt; 1.5 ) primary ovarian failure ( elevated FSH ) On medication know affect hormone measure glucocorticoid anti seizure medication thyroid hormone estrogen ( must least 3 month prior participate study ) A known history anaphylaxis anaphylactoidlike reaction , know hypersensitivity E. Coli derive protein Breast feeding , pregnant , want become pregnant next 6 month . We screen condition detailed history system review , physical examination , laboratory evaluation ( described Screening Methods ) , EKG . In Reward Substudy subject ask fill standard BIDMC MRI safety screen form prior enter magnet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>leptin</keyword>
	<keyword>hypothalamic amenorrhea</keyword>
	<keyword>exercise-induced amenorrhea</keyword>
	<keyword>neuroendocrine function</keyword>
	<keyword>bone metabolism</keyword>
</DOC>